
Paola NisticÃ²

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9292611/publications.pdf Version: 2024-02-01



Ρλοιλ Νιστις Α2

#	Article	IF	CITATIONS
1	Actin Cytoskeleton and Regulation of TGFÎ ² Signaling: Exploring Their Links. Biomolecules, 2021, 11, 336.	4.0	17
2	Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology. Journal of Experimental and Clinical Cancer Research, 2021, 40, 102.	8.6	64
3	Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. Biology, 2021, 10, 913.	2.8	2
4	A cytofluorimetric assay to evaluate T cell polyfunctionality. Methods in Enzymology, 2020, 631, 61-76.	1.0	0
5	Cross-reactivity between tumor MHC class l–restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	12.6	217
6	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 89.	8.6	157
7	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Frontiers in Oncology, 2020, 10, 202.	2.8	6
8	Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. International Journal of Biological Markers, 2020, 35, 8-11.	1.8	15
9	Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. Communications Biology, 2020, 3, 85.	4.4	36
10	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ ⁻ ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	2.2	8
11	The actin modulator <scp>hMENA</scp> regulates <scp>GAS</scp> 6― <scp>AXL</scp> axis and proâ€ŧumor cancer/stromal cell cooperation. EMBO Reports, 2020, 21, e50078.	4.5	20
12	Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. Journal of Translational Medicine, 2019, 17, 131.	4.4	17
13	3D models in the new era of immune oncology: focus on T cells, CAF and ECM. Journal of Experimental and Clinical Cancer Research, 2019, 38, 117.	8.6	78
14	Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer. Frontiers in Immunology, 2019, 10, 729.	4.8	101
15	hMENA is a key regulator in endothelin-1/β-arrestin1–induced invadopodial function and metastatic process. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3132-3137.	7.1	21
16	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. Oncolmmunology, 2018, 7, e1465163.	4.6	6
17	hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis. Oncogene, 2018, 37, 5605-5617.	5.9	17
18	IL-18 receptor marks functional CD8 ⁺ T cells in non-small cell lung cancer. Oncolmmunology, 2017, 6, e1328337.	4.6	23

Paola NisticÃ²

#	Article	IF	CITATIONS
19	Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Journal of Hematology and Oncology, 2017, 10, 16.	17.0	101
20	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486.	2.6	5
21	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine and Growth Factor Reviews, 2017, 36, 67-77.	7.2	71
22	The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome. Oncolmmunology, 2016, 5, e1221556.	4.6	23
23	Polyfunctional Melan-A-specific tumor-reactive CD8 ⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncolmmunology, 2016, 5, e1114203.	4.6	25
24	hMENA ^{11a} , a hMENA isoform sending survival signals. Molecular and Cellular Oncology, 2016, 3, e1083648.	0.7	2
25	hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. Oncogene, 2016, 35, 887-896.	5.9	13
26	Abstract A003: Polyfunctional antitumor CD8 T cells obtained from a broad repertoire elicited by chemo-immunotherapy and preventing melanoma relapse depends on the activation of an AKT pathway sustained by ICOS. , 2016, , .		0
27	Abstract A113: The pattern of hMENA isoforms is regulated by TGF- \hat{l}^21 in pancreatic cancer and may predict patient outcome. , 2016, , .		0
28	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. Oncogene, 2015, 34, 2493-2504.	5.9	59
29	Abstract 4316: hMENA11acontributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. , 2015, , .		1
30	Abstract A60: The hMENA Splicing Program: An important regulator of TGF1^21-driven EMT and invasiveness in pancreatic cancer. , 2015, , .		0
31	β1 and β4 integrins: from breast development to clinical practice. Breast Cancer Research, 2014, 16, 459.	5.0	57
32	hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?. Journal of Translational Medicine, 2014, 12, .	4.4	0
33	Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. Oncotarget, 2014, 5, 11054-11063.	1.8	32
34	Abstract 1035: <code>hMENA</code> splicing program and TGF- \hat{l}^21 -mediated EMT in pancreatic cancer. , 2014, , .		0
35	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. Journal of Hematology and Oncology, 2013, 6, 67.	17.0	42
36	Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19280-19285.	7.1	112

PAOLA NISTICÃ²

#	Article	IF	CITATIONS
37	Molecular and Genetic Bases of Pancreatic Cancer. Current Drug Targets, 2012, 13, 731-743.	2.1	24
38	Epithelial-Mesenchymal Transition: General Principles and Pathological Relevance with Special Emphasis on the Role of Matrix Metalloproteinases. Cold Spring Harbor Perspectives in Biology, 2012, 4, a011908-a011908.	5.5	231
39	Abstract 4406: Clinical efficacious combined chemo/immunotherapy differently activates AKT pathway and functionality of gp100 and Melan-A specific T cell clones. , 2012, , .		ο
40	Circulating Autoantibodies to Phosphorylated α-Enolase are a Hallmark of Pancreatic Cancer. Journal of Proteome Research, 2011, 10, 105-112.	3.7	119
41	Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A–Specific, Tumor-Reactive CTL in Melanoma Patients. Cancer Research, 2010, 70, 7084-7092.	0.9	57
42	The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer. PLoS ONE, 2010, 5, e15852.	2.5	23
43	Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model Journal of Clinical Oncology, 2010, 28, 7027-7027.	1.6	1
44	Chemotherapy enhances vaccineâ€induced antitumor immunity in melanoma patients. International Journal of Cancer, 2009, 124, 130-139.	5.1	103
45	An integrated humoral and cellular response is elicited in pancreatic cancer by αâ€enolase, a novel pancreatic ductal adenocarcinomaâ€associated antigen. International Journal of Cancer, 2009, 125, 639-648.	5.1	115
46	Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion inÂvivo. Clinical and Experimental Metastasis, 2009, 26, 153-159.	3.3	107
47	Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. Journal of Translational Medicine, 2009, 7, 21.	4.4	32
48	Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. Clinical Cancer Research, 2008, 14, 4943-4950.	7.0	63
49	Imaging laser diffractometer for traceable grating pitch calibration. Measurement Science and Technology, 2007, 18, 375-383.	2.6	22
50	Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena+11a Phosphorylation in Breast Cancer Cell Lines. Cancer Research, 2007, 67, 2657-2665.	0.9	80
51	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. Journal of Proteome Research, 2007, 6, 4025-4031.	3.7	88
52	The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors. Clinical Cancer Research, 2006, 12, 1470-1478.	7.0	73
53	Human mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+T-cell immune response. International Journal of Cancer, 2004, 109, 909-918.	5.1	78
54	Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer. Journal of Immunotherapy, 2001, 24, 221-231.	2.4	0

Paola NisticÃ²

#	Article	IF	CITATIONS
55	Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. International Journal of Cancer, 1999, 84, 598-603.	5.1	12
56	Low Frequency of ErbB-2 Proto-oncogene Overexpression in Human Leukocyte Antigen-A2-Positive Breast Cancer Patients. Journal of the National Cancer Institute, 1997, 89, 319-321.	6.3	13
57	MHC-Peptide Binding. Journal of Immunotherapy, 1997, 20, 431-436.	2.4	8
58	Melan-A/MART-1 Antigen Expression in Cutaneous and Ocular Melanomas. Journal of Immunotherapy, 1997, 20, 466-469.	2.4	15
59	α6β4 and α6β1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines. Experimental Cell Research, 1997, 236, 76-85.	2.6	201
60	Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway Journal of Clinical Investigation, 1994, 94, 1426-1431.	8.2	9
61	Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma Journal of Clinical Investigation, 1992, 90, 1093-1099.	8.2	15
62	Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. International Journal of Cancer, 1990, 46, 539-545.	5.1	24
63	Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2941-2945.	7.1	20